| Size | Price | |
|---|---|---|
| 25mg | ||
| 50mg | ||
| 100mg | ||
| 250mg |
Purity: ≥98%
| Targets |
The primary target of CMPD 7 is cyclin-dependent kinase 12 (CDK12). CDK12 is involved in the regulation of transcription, including the phosphorylation of the C-terminal domain (CTD) of RNA polymerase II. CMPD 7 is a highly potent and selective CDK12 inhibitor with an IC50 of 491 nM. It shows selectivity over other CDKs, including CDK2 (5-fold) and CDK9 (nearly 20-fold).
|
|---|---|
| ln Vitro |
CDK12-IN-3 is a CDK12 reagent that is very sensitive. Strong suppression of Ser2 phosphorylation on RNA Pol II's CTD repeat domain, together with OV90 cell growth inhibition and THP1 cell acute cytotoxicity, are demonstrated by CDK12-IN-3 (0.1 μM) [1].
CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in an enzymatic assay. It was profiled against a panel of 352 kinases at 0.1 µM and showed high selectivity for CDK12. The compound demonstrates 5-fold selectivity over CDK2 and nearly 20-fold selectivity over CDK9. Specific cellular activity data (e.g., IC50 for inhibition of cell proliferation) are not provided in the available sources. |
| ln Vivo |
In vivo activity data for CMPD 7 are not detailed in the available sources. The compound's primary characterization comes from in vitro enzymatic and selectivity assays. As a CDK12 inhibitor, it may have potential applications in cancer research, given the role of CDK12 in transcriptional regulation and genomic stability. However, specific in vivo efficacy studies have not been described.
|
| Enzyme Assay |
The CDK12 enzymatic assay for CMPD 7 involves incubating the compound with recombinant CDK12/cyclin K complex, ATP, and a peptide substrate (e.g., a CTD peptide). The reaction is carried out in a kinase buffer optimized for CDK12. After incubation, the amount of phosphorylated substrate is quantified using a luminescence-based kinase assay (e.g., ADP-Glo) or HTRF. IC50 values are calculated from dose-response curves generated with varying concentrations of the compound.
|
| Cell Assay |
Specific cellular assay protocols for CMPD 7 are not detailed in the available sources. The compound's selectivity was profiled against a panel of 352 kinases at 0.1 µM, indicating that cellular assays may have been performed to assess its effects on CDK12-mediated phosphorylation and downstream signaling. Typical cellular assays would involve treating cancer cells with the compound and measuring CDK12 activity, RNA polymerase II CTD phosphorylation, or cell proliferation.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for CMPD 7 are not detailed in the available sources. The compound has not been described in the context of xenograft models or other in vivo efficacy studies. Given its in vitro activity as a selective CDK12 inhibitor, it may be evaluated in standard xenograft models in future studies, but such data are not currently available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for CMPD 7 are not provided in the available sources. The compound is a small molecule with a molecular weight of 470.53. Standard pharmacokinetic studies would typically involve administering the compound to rodents and measuring plasma concentrations over time using LC-MS/MS to determine key PK parameters, but such data are not currently available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for CMPD 7 are not provided in the available sources. As a research compound, it is intended for laboratory use only and is not approved for human therapeutic applications. The compound is available with a purity of ≥98%. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
CMPD 7 is also known as AZ1992. It is a novel, highly potent, and selective CDK12 inhibitor with an IC50 of 491 nM in an enzymatic assay. It shows 5-fold selectivity over CDK2 and nearly 20-fold selectivity over CDK9. The compound was profiled against a panel of 352 kinases at 0.1 µM. It has a CAS number of 2220184-50-7 and is supplied for research purposes.
|
| Molecular Formula |
C23H28F2N8O
|
|---|---|
| Molecular Weight |
470.518230438232
|
| Exact Mass |
470.235
|
| CAS # |
2220184-50-7
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.4
|
| SMILES |
FC1=C(C=CC2=C1N=C(CNC1C3=C(N(C=N3)C(C)C)N=C(N=1)N1CCCCC1CCO)N2)F
|
| InChi Key |
KULPPFCRBINTBS-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C23H28F2N8O/c1-13(2)33-12-27-20-21(26-11-17-28-16-7-6-15(24)18(25)19(16)29-17)30-23(31-22(20)33)32-9-4-3-5-14(32)8-10-34/h6-7,12-14,34H,3-5,8-11H2,1-2H3,(H,28,29)(H,26,30,31)/t14-/m0/s1
|
| Chemical Name |
(S)-2-(1-(6-(((6,7-Difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-isopropyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol
|
| Synonyms |
CMPD7;CMPD 7; CMPD-7; AZ1992; AZ-1992; AZ 1992; Compound 7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~531.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.33 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.33 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1253 mL | 10.6265 mL | 21.2531 mL | |
| 5 mM | 0.4251 mL | 2.1253 mL | 4.2506 mL | |
| 10 mM | 0.2125 mL | 1.0627 mL | 2.1253 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA